TY - JOUR
T1 - a multicenter total therapy strategy for de novo adul Philadelphia chromosome positive acute lymphoblastic leukemia patients.
AU - Sica, Simona
PY - 2021
Y1 - 2021
N2 - The GIMEMA LAL1509 protocol, designed for adult (≥18-60 years) de novo Ph+ acute
lymphoblastic leukemia patients, was based on a dasatinib plus steroids induction - with central
nervous system prophylaxis - followed by dasatinib alone in patients in complete molecular
response or chemotherapy and/or allogeneic transplantation in patients not reaching a complete
molecular response. Sixty patients (median age 41.9 years) were enrolled: 33 were p190+, 18
p210+ and 9 p190/p210+. At the end of induction (day +85), 58 patients (97%) achieved a
complete hematologic remission. No deaths in induction were recorded. Eleven patients (18.3%)
obtained a complete molecular response. Among non-complete molecular responders (n=47), 22
underwent an allogeneic transplant. Seventeen hematologic relapses occurred (median 7 months,
range 3-40.1), 13 during consolidation and 4 post-transplant. ABL1 mutations (5 T315I, 3 V299L, 1
E281K and 1 G254E) were found in 10/13 relapsed cases. With a median follow-up of 57.4 months
(range: 4.2-75.6), overall survival and disease-free survival are 56.3% and 47.2%. A better diseasefree
survival was observed in patients who obtained a molecular response at day +85 compared to
AB - The GIMEMA LAL1509 protocol, designed for adult (≥18-60 years) de novo Ph+ acute
lymphoblastic leukemia patients, was based on a dasatinib plus steroids induction - with central
nervous system prophylaxis - followed by dasatinib alone in patients in complete molecular
response or chemotherapy and/or allogeneic transplantation in patients not reaching a complete
molecular response. Sixty patients (median age 41.9 years) were enrolled: 33 were p190+, 18
p210+ and 9 p190/p210+. At the end of induction (day +85), 58 patients (97%) achieved a
complete hematologic remission. No deaths in induction were recorded. Eleven patients (18.3%)
obtained a complete molecular response. Among non-complete molecular responders (n=47), 22
underwent an allogeneic transplant. Seventeen hematologic relapses occurred (median 7 months,
range 3-40.1), 13 during consolidation and 4 post-transplant. ABL1 mutations (5 T315I, 3 V299L, 1
E281K and 1 G254E) were found in 10/13 relapsed cases. With a median follow-up of 57.4 months
(range: 4.2-75.6), overall survival and disease-free survival are 56.3% and 47.2%. A better diseasefree
survival was observed in patients who obtained a molecular response at day +85 compared to
KW - a multicenter total therapy strategy for de novo adul Philadelphia chromosome positive acute lymphoblastic leukemia patients.
KW - a multicenter total therapy strategy for de novo adul Philadelphia chromosome positive acute lymphoblastic leukemia patients.
UR - http://hdl.handle.net/10807/169841
M3 - Article
SN - 0390-6078
SP - 1
EP - 1
JO - Haematologica
JF - Haematologica
ER -